Global Locations

Remdesivir Alanine D4



Chemical Properties of 'Remdesivir Alanine D4'

CAT No. :

CS-T-93681
CAS Registry No. : 1809249-37-3 (Unlabeled)
Category : Isotope Labelled Compounds
Molecular Weight: 620.63 g/mol
Molecular Formula : C28H33D4N6O8P



OTHER INFORMATION of 'Remdesivir Alanine D4'
Therapeutic : COVID19
Therapeutic : COVID19
IUPAC Name :2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
Smileys :N#C[C@@]1(C2=CC=C3C(N)=NC=NN32)O[C@H](COP(OC4=CC=CC=C4)(N[C@](C(OCC(CC)CC)=O)(C([2H])([2H])[2H])[2H])=O)[C@@H](O)[C@H]1O
Use Classification :Human drugs -> Veklury -> EMA Drug Category
Hazard Class :STOT RE 1 (66.67%)
EC Number :852-825-8
UNII :3QKI37EEHE
NCI Thesaurus Code :C152185
RXCUI :2284718
MeSH Entry Terms :(13C3)-GS-5734
Other Synonyms :1809249-37-3
Removed Synonyms :Remdesivir intermediates
Label Ingredient : REMDESIVIR
NDC Code :61958-2901-1, 61958-2901-2, 61958-2902-1, 61958-2902-2
Toxicity Summary :Data regarding overdoses of remdesivir are not readily available. Overdoses of other nucleoside analogs like acyclovir can be managed with symptomatic and supportive treatment.
Hepatotoxicity :In human volunteer studies, remdesivir therapy given for 7 to 14 days was associated with minor serum aminotransferase elevations (less than 5 times ULN) but without other evidence of hepatic injury. In controlled trials of remdesivir in patients hospitalized with COVID-19, rates of serum ALT elevations were similar or lower in patients receiving remdesivir than in those on placebo. Nevertheless, in most uncontrolled studies and case series, between 10% and 50% of patients treated with remdesivir developed transient, mild-to-moderate serum ALT and AST elevations within 1 to 5 days of starting therapy without changes in serum bilirubin or alkaline phosphatase levels. Elevations above 5 times ULN were reported in up to 9% of patients in several clinical trials, but the abnormalities resolved with discontinuation and were not associated with clinically apparent injury. With more widespread use of remdesivir for COVID-19, rare instances of marked ALT elevations with jaundice have been reported, but largely in patients who were critically ill with multi-organ failure or sepsis, or who had received other potentially hepatotoxic agents such as intravenous amiodarone (Case 2). Confounding the issue is that serum aminotransferase elevations are common during symptomatic SARS-CoV-2 infection (Case 1), present in up to 60% of patients and being more frequent in patients with severe disease and in those with the known risk factors for COVID-19 severity such as male sex, older age, higher body mass index and diabetes. Thus, serum aminotransferase elevations are common during remdesivir therapy but are generally asymptomatic, fully reversible and not associated with jaundice. With more widespread use of this antiviral in patients without severe or critical illness and with longer courses of therapy, features of hepatotoxicity may become more evident.
Protein Binding :Remdesivir is 88-93.6% bound to human plasma proteins while its metabolites [GS-441524] and GS-704277 are 2% and 1% bound, respectively.
Exact Mass :602.22539909
InChI :InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
InchIKey :RWWYLEGWBNMMLJ-YSOARWBDSA-N
Canonical SMILES :CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
Isomeric SMILES :CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
Product Description :Remdesivir is a carboxylic ester resulting from the formal condensation of the carboxy group of N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alanine with the hydroxy group of 2-ethylbutan-1-ol. A broad-spectrum antiviral prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola virus, MERS-CoV and SARS-CoV. It is currently in Phase III clinical trials for the treatment of Covid-19 in adults. It has a role as an antiviral drug, a prodrug and an anticoronaviral agent. It is a carboxylic ester, a pyrrolotriazine, a nitrile, a phosphoramidate ester, a C-nucleoside and an aromatic amine. It derives from a GS-441524.
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back


More information about Alanine






This page contains information about Remdesivir Alanine D4 , Remdesivir Alanine D4 cas, Remdesivir Alanine D4 synthesis, Remdesivir Alanine D4 suppliers

What is Remdesivir Alanine D4 ?
Remdesivir Alanine D4 falls under Isotope Labelled Compounds of Alanine.
What is the CAS Number of Remdesivir Alanine D4?
The CAS Number of Remdesivir Alanine D4 is 1809249-37-3 (Unlabeled)
Who are the suppliers of Remdesivir Alanine D4?
CLEARSYNTH is a worldwide supplier of Remdesivir Alanine D4

Related compounds of Remdesivir Alanine D4

Looking for a discounted price or need more info for 'Remdesivir Alanine D4 (CS-T-93681)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Remdesivir Alanine D4 (CS-T-93681)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.